Table 2.
Phenotype of NK cells in pre- and post-treatment PBMC compared to the infused cell populations
| Patient | % NK cellsa |
% CD16+ NK cells (MFI)b |
% NKG2D+ NK cells (MFI)c |
|||||
|---|---|---|---|---|---|---|---|---|
| Infused cells | 1 week post-Rx PBMC | Pre-Rx PBMC | Infused cells | 1 week post-Rx PBMC | Pre-Rx PBMC | Infused cells | 1 week post-Rx PBMC | |
| 1 | 97 | 90 | 75 (534) | ntd | 37 (136) | 79 (214) | nt | 50 (130) |
| 2 | 96 | 91 | nt | nt | 45 (172) | nt | nt | 59 (149) |
| 3 | 96 | 86 | 68 (279) | 55 (125) | 42 (149) | 21 (79) | 100 (884) | 14 (66) |
| 4 | 98 | 71 | 76 (325) | 33 (64) | 26 (44) | 42 (100) | 97 (440) | 18 (64) |
| 5 | 97 | 55 | 77 (430) | 47 (129) | 16 (43) | 66 (149) | 100 (778) | 20 (65) |
| 6 | 93 | 93 | 54 (271) | nt | 35 (122) | 37 (96) | nt | 29 (80) |
| 7 | 97 | 93 | 91 (675) | 63 (213) | 65 (266)e | 53 (140) | 98 (540) | 36 (109)e |
| 8 | 95 | 82 | 77 (610) | 42 (135) | 35 (108) | 78 (248) | 100 (1572) | 62 (153) |
%NK cells in infused cell populations was determined by FACS as the % PI- CD3- CD56+ cells. %NK cells in post-treatment PBMC samples approximately 1 week after treatment (day 7 or 8) was determined by the Hematology and Immunology Flow Cytometry Laboratories within the Department of Laboratory Medicine at the NIH Clinical Center as the number of CD3- cells that expressed either CD56 or CD16 as a percentage of the absolute lymphocyte count (ALC).
CD16 expression on the indicated cell populations was evaluated by FACS after gating on CD3- CD56+ cells.
NKG2D expression on the indicated cell populations was evaluated by FACS after gating on CD3- CD56+ cells.
“nt” indicated not tested due to limited sample availability.
For Patient 7, the 1 week post-treatment PBMC sample analyzed for CD16 and NKG2D expression was obtained 10 days after treatment since 7 or 8 day samples were not available.